+ Watch ADLS
on My Watchlist
A biopharmaceutical company focused on the discovery, development and commercialization of novel drugs in the areas of infectious disease, oncology and inflammation.
Phase III results for Cethromycin looks good. Company planning on NDA submits in 3Q of this year but need a partnership to cover the 10M cost owned to Abbott upon filing of NDA. Company is undervalued right now but it all comes down to how good of a partnership deal they can negotiate. PPS has dropped low enough for me to make a gamble.
If you are new to ADLS this is well worth reading in your DD efforts. Read the entire document and you will have a decent picture of the potential for Cethromycin. Incidentally, the reason the NDA was delayed until Oct of 2008 was the liver toxicity issues that surfaced with Ketek (a molecularly different ketolide antibiotic that was approved in 2004) and the need to further study Cethromycin (Restanza) in comparison to Ketek. The results of these studies are released in the FDA panel briefing document that was in the news on Friday. By my reading liver tox is not longer an issue on the table for Cethromycin and there were no other damaging safety issues.http://google.brand.edgar-online.com/EFX...On Tuesday June 2 ALS is meeting with the FDA anti-infective drug panel to review the safety & efficacy of Restanza. A vote of the panel will be taken at the end of that meeting. I anticipate that this vote will be majority positive and will set the stage for additional milestone events including a settlement of the arbitration issues currently in play with Abbott and a domestic or European commercialization agreement with a major Pharm.IMO, ADLS is a very safe bet at this level and within this time frame and a revaluation to the mid 2 dollar range before the end of next week is likely. There is sufficient additional potential impetus to move the PPS into the mid 3's and perhaps beyond during the coming 6 months. A relisting to the NASDAQ is likely during the coming 90 days. GLA....G
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions